Current approach on COVID-19 and other vaccinations in previous MIS-C/PIMS: a MAS/sJIA and Vaccination WPs survey
1.
Which is your country of practice?
2.
Which is your center of practice?
3.
Which is your area of expertise?
general pediatrics
pediatric rheumatology
pediatric infectious disease
pediatric immunology
pediatric emergency care
pediatric cardiology
Other (please specify)
4.
How many patients with MIS-C/PIMS have been treated in your centre?
< 5
5-20
20-50
> 50
data not available
5.
Is anti SARS-CoV-2 vaccine available for children in your country?
yes, for children > 16 years old
yes, for children > 12 years old
no
6.
Have you vaccinated any children with previous MIS-C/PIMS with anti SARS-CoV-2 vaccine at your centre?
Yes
No
7.
If you answered yes to Question 6, how many children with previous MIS-C/PIMS have you vaccinated with anti SARS-CoV-2 vaccine at your centre?
<5
5-10
> 10
data not available
Not applicable
8.
If you answered yes to Question 6, did you observe any side effects after anti SARS-CoV-2 vaccine in patients with previous MIS-C/PIMS?
Yes
No
data not available
Not applicable
If yes, please specify:
9.
How many patients of yours with previous MIS-C/PIMS got COVID-19 infection again?
None
<2
2-5
<5
data not available
10.
If you answered yes to Question 9, how many of them did present a MIS-C/PIMS relapse?
None
<2
2-5
>5
data not available
Not applicable
11.
If you vaccinated or aim to vaccinate with anti SARS-CoV-2 vaccine patients with previous MIS-C/PIMS, what would, in your opinion, be a reasonable timing for the 1st booster vaccination?
between 3-6 months after MIS-C/PIMS
between 6-12 months after MIS-C/PIMS
later than 12 months after MIS-C/PIMS
I will not vaccinate patients with previous MISC/PIMS
Comments:
12.
Which variables do impact on your decision
not
to vaccinate with anti SARS-CoV-2 vaccine a patient with previous MIS-C/PIMS? (multiple choice possible)
current lack of evidence
fear of relapse
patient/parent decision
local specific recommendation against
ongoing immunosuppressive treatment
presence of still positive SARS-CoV-2 serology
excessive proximity to MIS-C/PIMS episode
history of severe MISC/PIMS
history of severe MISC/PIMS with myocarditis
Other (please specify)
13.
Which variables do you consider most relevant in your decision to vaccinate with anti SARS-CoV-2 vaccine a patient with previous MIS-C/PIMS? (multiple choice possible)
time from MIS-C/PIMS episode
SARS-CoV-2 serologic status
ongoing immunosuppressive treatment
MIS-C/PIMS features
Other or comments (please specify)
14.
Would you consider to continue regular vaccinations with non-live vaccines according to the national vaccination program in a child with previous MIS-C/PIMS?
Yes
Yes, but not before 3 months after MIS-C/PIMS
Yes, but not before 6 months after MIS-C/PIMS
Yes, but not before 12 months after MIS-C/PIMS
No
Comments:
15.
Would you consider to continue regular vaccinations with live attenuated vaccines according to the national vaccination program in a child with previous MIS-C/PIMS?
Yes
Yes, but not before 3 months after MIS-C/PIMS
Yes, but not before 6 months after MIS-C/PIMS
Yes, but not before 12 months after MIS-C/PIMS
No
Comments: